NRx Pharmaceuticals, Inc.
NRXP
$3.28
$0.072.18%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -3.25% | -13.20% | -16.87% | -3.83% | -5.02% |
| Depreciation & Amortization | 2,166.67% | 1,250.00% | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.62% | -24.44% | -39.24% | -27.73% | -28.58% |
| Operating Income | 17.84% | 25.63% | 39.24% | 27.73% | 28.58% |
| Income Before Tax | -13.92% | -86.76% | -36.16% | 5.96% | 16.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.92% | -86.76% | -36.16% | 5.96% | 16.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.92% | -86.76% | -36.16% | 5.96% | 16.66% |
| EBIT | 17.84% | 25.63% | 39.24% | 27.73% | 28.58% |
| EBITDA | 18.09% | 25.67% | 39.25% | 27.74% | 28.58% |
| EPS Basic | 34.01% | -6.81% | 20.27% | 38.37% | 42.43% |
| Normalized Basic EPS | 43.86% | 25.85% | 34.95% | 39.19% | 38.94% |
| EPS Diluted | 34.01% | -6.81% | 20.27% | 38.74% | 42.70% |
| Normalized Diluted EPS | 43.86% | 25.85% | 34.95% | 39.19% | 38.94% |
| Average Basic Shares Outstanding | 100.81% | 79.17% | 61.55% | 54.60% | 40.88% |
| Average Diluted Shares Outstanding | 100.81% | 79.17% | 61.55% | 54.60% | 40.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |